Kappa Opioid Receptor Availability, Social Rank, and Cocaine Self-Administration in Female and Male Monkeys

可卡因使用障碍（CUD）一直是一个世界范围内的公共卫生问题，没有得到fda的批准

Cocaine use disorder (CUD) persists as a worldwide public health problem for which there is no FDA-approved pharmacotherapy. Of clinical significance, in the US, cocaine use is increasing, alongside cocaine overdose deaths, which have more than tripled from 2012 to 2018 [1, 2]. A gap in the literature and the primary focus of this application, is to extend research from the dopamine system, associated with euphoria, to the dynorphin/kappa opioid receptor (KOR) system, implicated in the “dark side” of addiction. This research project utilizes a highly homologous nonhuman primate model, incorporating social behavior with intravenous drug self- administration (SA) and positron emission tomography (PET), in drug-naive female and male monkeys. The proposed longitudinal, within-subject study design will further our understanding of the neurobiology associated with the vulnerability and maintenance of cocaine abuse. The initial Aim 1 of this proposal used PET imaging with a KOR radiotracer, [11C]EKAP, to obtain baseline measures of KOR availability and assess the relationship between KOR availability and social rank in cocaine-naïve male and female monkeys. The studies in that Aim have been completed. Overall, the lowest receptor availability across all regions of interest were observed in dominant females and subordinate males; based on previous studies, the two most vulnerable phenotypes to cocaine reinforcement. The baseline assessment of KOR measures allows the ability to assess the relationship between receptor availability and vulnerability of cocaine abuse (Aim 1), as well as how those measures change following chronic cocaine self-administration (Aim 2). In addition, the studies in Aim 3 will assess clinically relevant factors associated with withdrawal/abstinence and assess the neural plasticity of KOR system following protracted abstinence. The use of PET as a biomarker related to vulnerability and treatment outcome may provide evidence for a personalized medicine approach to treating CUD.